Taylor Sandison

1.4k total citations
49 papers, 902 citations indexed

About

Taylor Sandison is a scholar working on Infectious Diseases, Epidemiology and Plant Science. According to data from OpenAlex, Taylor Sandison has authored 49 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 13 papers in Epidemiology and 10 papers in Plant Science. Recurrent topics in Taylor Sandison's work include Antifungal resistance and susceptibility (29 papers), Fungal Infections and Studies (10 papers) and Nematode management and characterization studies (9 papers). Taylor Sandison is often cited by papers focused on Antifungal resistance and susceptibility (29 papers), Fungal Infections and Studies (10 papers) and Nematode management and characterization studies (9 papers). Taylor Sandison collaborates with scholars based in United States, Spain and Uganda. Taylor Sandison's co-authors include Voon Ong, Dirk Thye, Emmanuel Arinaitwe, Humphrey Wanzira, Abel Kakuru, Jordan W. Tappero, Grant Dorsey, Stephen E. Hawes, Chia C. Wang and Steven A. Pergam and has published in prestigious journals such as Blood, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Taylor Sandison

47 papers receiving 874 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Taylor Sandison United States	17	504	444	256	88	81	49	902
Jackson Mukonzo Uganda	17	467 0.9×	186 0.4×	120 0.5×	23 0.3×	131 1.6×	49	1.0k
John Marcinak United States	19	684 1.4×	403 0.9×	334 1.3×	57 0.6×	13 0.2×	52	1.4k
Borimas Hanboonkunupakarn Thailand	20	205 0.4×	114 0.3×	630 2.5×	40 0.5×	32 0.4×	63	995
Dénise P. Ilboudo Burkina Faso	16	173 0.3×	242 0.5×	95 0.4×	134 1.5×	135 1.7×	40	757
Kayla R. Stover United States	17	341 0.7×	309 0.7×	206 0.8×	22 0.3×	17 0.2×	96	999
Erasmus Kamugisha Tanzania	20	193 0.4×	263 0.6×	454 1.8×	26 0.3×	12 0.1×	48	1.1k
Evans Amukoye Kenya	15	458 0.9×	453 1.0×	300 1.2×	18 0.2×	8 0.1×	43	992
Sónia Machevo Spain	20	234 0.5×	349 0.8×	490 1.9×	39 0.4×	8 0.1×	31	1.2k
Usha Arora India	14	177 0.4×	159 0.4×	238 0.9×	50 0.6×	41 0.5×	54	636
Ka-Tim Choy Hong Kong	11	606 1.2×	320 0.7×	43 0.2×	12 0.1×	62 0.8×	14	1.1k

Countries citing papers authored by Taylor Sandison

Since Specialization

Citations

This map shows the geographic impact of Taylor Sandison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taylor Sandison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taylor Sandison more than expected).

Fields of papers citing papers by Taylor Sandison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taylor Sandison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taylor Sandison. The network helps show where Taylor Sandison may publish in the future.

Co-authorship network of co-authors of Taylor Sandison

This figure shows the co-authorship network connecting the top 25 collaborators of Taylor Sandison. A scholar is included among the top collaborators of Taylor Sandison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taylor Sandison. Taylor Sandison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Andes, David R., Roger J. M. Brüggemann, Shawn D. Flanagan, et al.. (2024). The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics. Journal of Antimicrobial Chemotherapy. 80(1). 18–28. 7 indexed citations

Cornely, Oliver A., George R. Thompson, Àlex Soriano, et al.. (2024). P29 Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and/or invasive candidiasis: integrated analysis of pooled Phase 2 and Phase 3 data. JAC-Antimicrobial Resistance. 6(Supplement_1). 1 indexed citations

Honoré, Patrick M., Matteo Bassetti, Oliver A. Cornely, et al.. (2024). Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials. Critical Care. 28(1). 361–361. 5 indexed citations

Honoré, Patrick M., Massimo Girardis, Marin H. Kollef, et al.. (2024). Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials. Critical Care. 28(1). 348–348. 4 indexed citations

Sandison, Taylor, António Ramos, Young Keun Kim, Louis Yi Ann Chai, & Monica A. Slavin. (2023). P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis. JAC-Antimicrobial Resistance. 5(Supplement_2). 1 indexed citations

Thompson, George R., Àlex Soriano, Patrick M. Honoré, et al.. (2023). Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. The Lancet Infectious Diseases. 24(3). 319–328. 43 indexed citations

Flanagan, Shawn D., et al.. (2022). 1694. Coadministration of Rezafungin Does Not Impact the Pharmacokinetics of Cyclosporine, Ibrutinib, Mycophenolate Mofetil, or Venetoclax. Open Forum Infectious Diseases. 9(Supplement_2). 2 indexed citations

Vázquez, José A., Shawn Flanagan, Peter G. Pappas, et al.. (2020). 637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin. Open Forum Infectious Diseases. 7(Supplement_1). S378–S379. 3 indexed citations

Thompson, George R., Juan Pablo Horcajada, Jeffrey B. Locke, et al.. (2020). 1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin. Open Forum Infectious Diseases. 7(Supplement_1). S657–S658. 2 indexed citations

10.

Corey, Ralph, Gregory J. Moran, Richard V. Goering, et al.. (2019). Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials. Diagnostic Microbiology and Infectious Disease. 94(3). 277–286. 5 indexed citations

11.

Bader, Justin, Elizabeth A. Lakota, Shawn D. Flanagan, et al.. (2018). Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata. Antimicrobial Agents and Chemotherapy. 62(6). 40 indexed citations

12.

Bensaci, Mekki, Shawn Flanagan, & Taylor Sandison. (2017). Determination of Tedizolid susceptibility interpretive criteria for gram-positive pathogens according to clinical and laboratory standards institute guidelines. Diagnostic Microbiology and Infectious Disease. 90(3). 214–220. 3 indexed citations

13.

Homsy, Jaco, Emmanuel Arinaitwe, Humphrey Wanzira, et al.. (2014). Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: a randomised controlled open-label trial. The Lancet Global Health. 2(12). e727–e736. 15 indexed citations

14.

Creek, Darren J., Victor Bigira, Emmanuel Arinaitwe, et al.. (2013). Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants. The Journal of Infectious Diseases. 207(11). 1646–1654. 19 indexed citations

15.

Creek, Darren J., Emmanuel Arinaitwe, Humphrey Wanzira, et al.. (2010). Increased Risk of Early Vomiting among Infants and Young Children Treated with Dihydroartemisinin-Piperaquine Compared with Artemether-Lumefantrine for Uncomplicated Malaria. American Journal of Tropical Medicine and Hygiene. 83(4). 873–875. 16 indexed citations

16.

Malamba, Samuel S., et al.. (2010). Plasmodium falciparum Dihydrofolate Reductase and Dihyropteroate Synthase Mutations and the Use of Trimethoprim-Sulfamethoxazole Prophylaxis among Persons Infected with Human Immunodeficiency Virus. American Journal of Tropical Medicine and Hygiene. 82(5). 766–771. 19 indexed citations

17.

Arinaitwe, Emmanuel, Taylor Sandison, Humphrey Wanzira, et al.. (2009). Artemether‐Lumefantrine versus Dihydroartemisinin‐Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan Children. Clinical Infectious Diseases. 49(11). 1629–1637. 100 indexed citations

18.

Pergam, Steven A., Chia C. Wang, Carolyn Gardella, et al.. (2008). Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. American Journal of Obstetrics and Gynecology. 199(1). 38.e1–38.e9. 111 indexed citations

19.

Eisert, Sheri, et al.. (2005). Using computerized clinical decision support for latent tuberculosis infection screening. American Journal of Preventive Medicine. 28(3). 281–284. 26 indexed citations

20.

Sandison, Taylor, Hendrika Meischke, Sheri M. Schaeffer, & Mickey S. Eisenberg. (2001). Barriers and facilitators to the prescription of automated external defibrillators for home use in patients with heart disease: A survey of cardiologists. Heart & Lung. 30(3). 210–215. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact